Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04823702 · ClinicalTrials.gov registry record · Phase 1
Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function
A Phase 1 study of Impaired Hepatic Function, sponsored by NGM Biopharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 3
- Study locations
NCT04823702: Completed Phase 1 study of Impaired Hepatic Function, sponsored by NGM Biopharmaceuticals.
NCT04823702 is a Phase 1 study of Impaired Hepatic Function that has completed, run by NGM Biopharmaceuticals. The registered enrollment target is 36 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04823702, a Phase 1 study of Impaired Hepatic Function, has completed, sponsored by NGM Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is an evaluation of Aldafermin (NGM282) in an open-label, single-dose and parallel group study in participants with Impaired Hepatic Function
Primary Outcome
Maximum observed plasma concentration (Cmax) of aldafermin (Day 1 through Day 4)
Conditions Studied
Interventions
- BIOLOGICAL Aldafermin
Study Locations (3)
Florida
- NGM Clinical Study Site 110 - Miami
- NGM Clinical Study Site 111 - Orlando
Texas
- NGM Clinical Study Site 113 - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2021-04-01 |
| Est. Completion | 2021-11-19 |
| Phase | Phase 1 |
What the finished NCT04823702 record still lists
NCT04823702 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower).
The record links to 1 condition, with Impaired Hepatic Function appearing as the primary indexed condition, and to 1 intervention - of which Aldafermin is the first listed.
NCT04823702 reports a single indexed study location in Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT04823702 about?
NCT04823702 is a clinical study titled "Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function". This is an evaluation of Aldafermin (NGM282) in an open-label, single-dose and parallel group study in participants with Impaired Hepatic Function
What is the current status of trial NCT04823702?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2021-04-01. Estimated completion is 2021-11-19.
What conditions does trial NCT04823702 study?
This clinical trial studies the following conditions: Impaired Hepatic Function.
What interventions are being tested in trial NCT04823702?
The interventions under investigation include: Aldafermin (BIOLOGICAL).
Who is sponsoring clinical trial NCT04823702?
This trial is sponsored by NGM Biopharmaceuticals, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04823702 being conducted?
This trial has 3 study locations across Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Impaired Hepatic Function
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04823702's enrollment target sits among peer trials
36 1210th of 2000 higher than 743 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI